Table 3.
Treatment characteristics of radiotherapy cohort
| SLNRT | ||||||
|---|---|---|---|---|---|---|
| Median PSA before LN RT | 1.3 (0.10–40.13) | |||||
| RT (Gy/median; range) | ||||||
| Former prostate | 66 (60–67.2) | |||||
| Lymphatic pathways | 50.4 (45.0–52.28) | |||||
| PET-positive local recurrence | 70 (68–70) | |||||
| PET-positive LN | 61.6 (50.4–66) | |||||
| RT technique | ||||||
| VMAT/IMRT & IGRT | 67 (100%) | |||||
| ADT with RT | 59 (88%) | |||||
| ADT with stop before last follow-up/median duration (months; range) |
42 (63%) 7 (2–41) |
|||||
| Ongoing ADT at last follow-up | 17 (25%) | |||||
| No ADT | 8 (12%) | |||||
| Toxicity | Acute toxicity | Late toxicity | ||||
| n (%) | n (%) | |||||
| Grade 2 | Grade 3 | Grade 4 | Grade 2 | Grade 3 | Grade 4 | |
| GU | 19 (28%) | 1 (2%) | – | 17 (25%) | 1 (2%) | – |
| GI | 19 (28%) | – | – | 1 (2%) | – | – |
| Other (erectile dysfunction) | 6 (9%) | 24 (36%) | ||||
SLNRT salvage lymph node radiotherapy, ADT androgen deprivation therapy, RT radiation therapy, VMAT volumetric modulated arc therapy, IMRT intensity-modulated radiotherapy, IGRT image-guided radiotherapy, LN lymph node, GU genitourinary, GI gastrointestinal